CymaBay Therapeutics Inc. (CBAY): Price and Financial Metrics
GET POWR RATINGS... FREE!
CBAY Stock Price Chart Interactive Chart >
CBAY Price/Volume Stats
|Current price||$2.95||52-week high||$4.74|
|Prev. close||$2.85||52-week low||$1.67|
|Day high||$2.97||Avg. volume||609,619|
|50-day MA||$2.19||Dividend yield||N/A|
|200-day MA||$3.16||Market Cap||249.80M|
CymaBay Therapeutics Inc. (CBAY) Company Bio
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex, Inc. The company was founded in 1988 and is based in Newark, California.
Most Popular Stories View All
CBAY Latest News Stream
|Loading, please wait...|
CBAY Latest Social Stream
View Full CBAY Social Stream
Latest CBAY News From Around the Web
Below are the latest news stories about CymaBay Therapeutics Inc that investors may wish to consider to help them evaluate CBAY as an investment opportunity.
NEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in two virtual investor conferences including the 11th Annual SVB Leerink Global Healthcare Conference taking place February 14-18, 2022 and Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-16, 2022. 11t
Although Albireo (ALBO) has an attractive and robust pipeline, I have focused mainly on Odevixibat in my articles so far. In my opinion, this is right, as the approved and revenue generating product Bylvay (Odevixibat in PFIC) is currently the biggest value driver for Albireo and actually justifies more than...
Investment company LCM Capital Management Inc (Current Portfolio) buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Duke Energy Corp, Xcel Energy Inc, sells Tesla Inc, Biogen Inc, Yum China Holdings Inc, UiPath Inc, CymaBay Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, LCM Capital Management Inc.
Trade Alert: The Chief Medical Officer Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Dennis Kim, Has Just Spent US$61k Buying A Few More Shares
Even if it's not a huge purchase, we think it was good to see that Dennis Kim, the Chief Medical Officer of CymaBay...
CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CBAY Price Returns